Delivering precision oncology to patients with cancer
Publication date
2022-04
Authors
Mateo, Joaquin
Steuten, Lotte
Aftimos, Philippe
André, Fabrice
Davies, Mark
Garralda, Elena
Geissler, Jan
Husereau, Don
Martinez-Lopez, Iciar
Normanno, Nicola
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
With the increasing use of genomic profiling for diagnosis and therapy guidance in many tumor types, precision oncology is rapidly reshaping cancer care. However, the current trajectory of drug development in oncology results in a paradox: if patients cannot access advanced diagnostics, we may be developing drugs that will reach few patients. In this Perspective, we outline the major challenges to the implementation of precision oncology and discuss critical steps toward resolving these, including facilitation of equal access to genomics tests, ensuring that clinical studies provide robust evidence for new drugs and technologies, enabling physicians to interpret genomics data, and empowering patients toward shared decision-making. A multi-stakeholder approach to evidence generation, value assessment, and healthcare delivery is necessary to translate advances in precision oncology into benefits for patients with cancer globally.
Keywords
Genomics/methods, Humans, Medical Oncology, Neoplasms/drug therapy, Precision Medicine/methods, Taverne, General Biochemistry,Genetics and Molecular Biology, Review, Research Support, Non-U.S. Gov't, Journal Article
Citation
Mateo, J, Steuten, L, Aftimos, P, André, F, Davies, M, Garralda, E, Geissler, J, Husereau, D, Martinez-Lopez, I, Normanno, N, Reis-Filho, J S, Stefani, S, Thomas, D M, Westphalen, C B & Voest, E 2022, 'Delivering precision oncology to patients with cancer', Nature Medicine, vol. 28, no. 4, pp. 658-665. https://doi.org/10.1038/s41591-022-01717-2